Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial

Paul M. Clément(Universitair Ziekenhuis Leuven), Jan B. Vermorken(University of Antwerp), Xiuyu Julie Cong(Boehringer Ingelheim (United States)), J. Guigay(Centre Antoine Lacassagne), Makoto Tahara(National Cancer Center Hospital East), Jérôme Fayette(Université Claude Bernard Lyon 1), Thomas Gauler, Lisa Licitra(University of Milan), Luciano de Souza Viana(Hospital de Câncer de Barretos), Ulrich Keilholz(German Cancer Research Center), Robert I. Haddad(Georgetown University), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Didier Cupissol(Institut de Recherche en Cancérologie de Montpellier), E. Ehrnrooth(Boehringer Ingelheim (Germany)), J.M. del Campo(Vall d'Hebron Hospital Universitari), Francesco Caponigro, Juan J. Grau(Hospital Clínic de Barcelona), J.-P. Machiels(Cliniques Universitaires Saint-Luc), Ezra E.W. Cohen(Moores Cancer Center)
Annals of Oncology
April 15, 2016
10.1093/annonc/mdw151
Cited by 45

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k